Skip to main content
Premium Trial:

Request an Annual Quote

Seegene Gets CE Mark for GI Infectious Disease Test

NEW YORK (GenomeWeb) – South Korea's Seegene announced on Monday that it has received CE-IVD marking for its Allplex Gastrointestinal Full Panel Assay, a multiplexed real-time PCR test for gastrointestinal infection.

The assay, which is now cleared for marketing in Europe and certain other regions, covers 25 bacterial, viral, and parasitic causes of gastrointestinal infectious disease.

"We are pleased to launch the Allplex GI assay in countries recognizing the CE mark," Seegene CEO Jong-Yoon Chun said in a statement. "As part of Seegene's global expansion initiatives in the molecular diagnostics market, we will continue to pursue a series of future submissions of other Allplex infectious disease tests in Europe, Canada, and the US markets."

Earlier this year, Seegene received Canadian approval for its respiratory disease assay and US approval for its herpes simplex virus 1 and 2 assay.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.